Activity of the neuroendocrine axes in patients with polymyalgia rheumatica before and after TNF-α blocking etanercept treatment
Open Access
- 15 August 2012
- journal article
- clinical trial
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 14 (4) , R186
Abstract
Introduction: In this study, we evaluated the activity of the neuroendocrine axes in patients with polymyalgia rheumatica (PMR) before and after tumor necrosis factor (TNF)-α-blocking etanercept treatment, which previously has been shown to reduce interleukin 6 (IL-6) and C-reactive protein (CRP) markedly in PMR. Methods: Plasma samples were collected from 10 glucocorticoid-naïve patients with PMR and 10 matched controls before and after etanercept treatment (25 mg biweekly for 2 weeks). The primary end points were pre- and posttreatment levels of adrenocorticotropic hormone (ACTH), cortisol, adrenaline, thyroid-stimulating hormone (TSH), follicle-stimulating hormone (FSH), prolactin, and insulin-like growth factor 1 (IGF-1). Results: Before TNF-α-blocking treatment, plasma TNF-α, ACTH, and cortisol levels were higher in patients versus controls (P < 0.05 and P < 0.001, respectively); during TNF-α blockade in patients, levels of both hormones decreased (P < 0.05 and P < 0.01, respectively), whereas levels in controls increased (P < 0.05), abolishing the pretreatment differences. Pretreatment adrenaline levels were more than twice as high in patients than in controls (P < 0.01); after treatment in patients, levels had decreased (P < 0.05) but remained higher versus controls (P < 0.05). Levels of the other hormones never differed significantly between groups (P > 0.05). Conclusions: In PMR, TNF-α may increase the activities of the hypothalamic-pituitary-adrenal and the hypothalamic-sympthoadrenomedullary axes. Secretion of TSH, FSH, prolactin, and IGF-1 is not clearly changed in PMR. Trial registration: ClinicalTrials.gov (NCT00524381).Keywords
This publication has 38 references indexed in Scilit:
- Increased muscle interstitial levels of inflammatory cytokines in polymyalgia rheumaticaArthritis & Rheumatism, 2010
- Improvement of Thyroid Function in Hypothyroid Patients with Rheumatoid Arthritis After 6 Months of Adalimumab Treatment: A Pilot StudyThe Journal of Rheumatology, 2010
- Effect of etanercept in polymyalgia rheumatica: a randomized controlled trialArthritis Research & Therapy, 2010
- Musculoskeletal aspects of hypoadrenalism: just a load of aches and pains?Clinical Rheumatology, 2009
- Serum cytokines and steroidal hormones in polymyalgia rheumatica and elderly-onset rheumatoid arthritisAnnals of the Rheumatic Diseases, 2006
- Neuroendocrine Modulation Induced by Selective Blockade of TNF‐α in Rheumatoid ArthritisAnnals of the New York Academy of Sciences, 2006
- Evaluation of the hypothalamic–pituitary–adrenal axis in untreated patients with polymyalgia rheumatica and healthy controlsScandinavian Journal of Rheumatology, 2006
- Endocrine aspects of acute and prolonged critical illnessNature Clinical Practice Endocrinology & Metabolism, 2006
- Long‐term anti–tumor necrosis factor antibody therapy in rheumatoid arthritis patients sensitizes the pituitary gland and favors adrenal androgen secretionArthritis & Rheumatism, 2003
- Leukocyte infiltration in synovial tissue from the shoulder of patients with polymyalgia rheumatica. Quantitative analysis and influence of corticosteroid treatmentArthritis & Rheumatism, 1996